Biotechnology News and Research

RSS

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

International biotechnology firm Cytonet, which is investigating a liver cell infusion of donated human liver cells for the treatment of urea cycle disorders in young children, announced it has been granted orphan drug designation by the U.S. Food and Drug Administration.

18 May 2011

Nano Bridging Molecules SA receives CE marking certification for SurfLink dental product

Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like’ and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.

18 May 2011

Excaliber subsidiary merges with VistaGen

Excaliber Enterprises, Ltd. announced today that its wholly-owned subsidiary has merged with VistaGen Therapeutics, Inc., a private biotechnology company focused on stem cell-based drug rescue and drug development. As a result of the Merger, VistaGen is a wholly-owned subsidiary of Excaliber.

17 May 2011

Pioneer of ‘organ-on-a-chip’ technology to speak at Imperial College London

The potential of microscopic organ-on-a-chip devices that mimic the way real organs work, so that scientists and engineers can model the effects of therapies more accurately, will be discussed by a pioneer in bioengineering at Imperial College London this week.

17 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

Columbia Laboratories to be listed on NASDAQ Biotechnology Index

Columbia Laboratories, Inc. today announced the Company will be added to the NASDAQ Biotechnology Index.

17 May 2011

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Life Technologies Corporation and ProBioGen AG today announced the availability of Gibco Freedom Cell Line Development Kits, a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.

17 May 2011

Epichem signs exclusive distributor agreement with AR Brown

Australian supplier of API analytical standards Epichem, announced today it has signed an exclusive distributor agreement with a leading Japanese Life Sciences supplier company, AR Brown, for sales to Japan, Taiwan, China and South Korea.

17 May 2011

Histogenics announces acquisition of ProChon Biotech

Histogenics Corporation, a privately held regenerative medicine company, announced today that it has acquired ProChon Biotech, Ltd. in a stock-for-stock exchange.

17 May 2011

Imec, VIB and KU Leuven join forces in pioneering brain research at NERF and in the Human Brain Project

Today, Flanders' ambitious brain research that may lead to better diagnosis and treatment of brain disease, new prosthesis technologies for patients with a disability, a new generation of more intelligent robots, etc. switches into higher gear. In the presence of Ingrid Lieten, Flemish Minister of Innovation, Public Procurement, the Media and Combatting Poverty, imec, VIB and K.U.Leuven officially inaugurated the NERF (Neuro-Electronics Research Flanders) labs on the Imec campus in Leuven. The Human Brain Project was also launched on this occasion, one of the projects on the shortlist of the prestigious European Flagship Programme. Through NERF and the participation of Flanders' research institutes in the Human Brain Project, Flanders shows that it is putting progressive brain research high on its research agenda.

16 May 2011

Aperio adds ScanScope AT to line of slide scanning instruments

Aperio, the global leader in providing digital pathology solutions that improve patient care, today announced the launch of the ScanScope AT, the latest addition to Aperio's industry-leading, patented line of ScanScope slide scanning instruments.

16 May 2011

Fluidigm launches 192.24 Dynamic Array integrated fluidic circuit for genome studies

Fluidigm Corporation today introduced its 192.24 Dynamic Array™ IFC, designed to genotype 192 samples against 24 SNP assays in a single run, providing 4,608 data points in just one hour. The 192.24 integrated fluidic circuit (IFC) has immediate applicability in agricultural biotechnology and genome wide association studies.

16 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Substances produced by living organisms found in nature-so-called "natural products"-have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

16 May 2011

Global health Product Development Partners consortium select GVK BIO as preferred provider

GVK Biosciences, Asia's leading drug discovery research & development organization announced today that it has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia. GVK BIO is the only partner that is headquartered in India.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Teva signs definitive agreement to acquire Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has signed a definitive agreement to acquire 57% of the shares in privately-held Taiyo Pharmaceutical Industry Co. Ltd. for $460 million in cash paid to private shareholders.

16 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

Biotechnology News and Research

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

Nano Bridging Molecules SA receives CE marking certification for SurfLink dental product

Excaliber subsidiary merges with VistaGen

Pioneer of ‘organ-on-a-chip’ technology to speak at Imperial College London

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Columbia Laboratories to be listed on NASDAQ Biotechnology Index

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Epichem signs exclusive distributor agreement with AR Brown

Histogenics announces acquisition of ProChon Biotech

Imec, VIB and KU Leuven join forces in pioneering brain research at NERF and in the Human Brain Project

Aperio adds ScanScope AT to line of slide scanning instruments

Fluidigm launches 192.24 Dynamic Array integrated fluidic circuit for genome studies

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Global health Product Development Partners consortium select GVK BIO as preferred provider

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Teva signs definitive agreement to acquire Taiyo

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News